Q3 EPS Forecast for Lisata Therapeutics Raised by Analyst

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Research analysts at Brookline Capital Management lifted their Q3 2025 EPS estimates for shares of Lisata Therapeutics in a report released on Monday, August 11th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.51) per share for the quarter, up from their previous forecast of ($0.66). Brookline Capital Management currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share. Brookline Capital Management also issued estimates for Lisata Therapeutics’ Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.09) EPS.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.11. The business had revenue of $0.07 million during the quarter.

Lisata Therapeutics Price Performance

Shares of LSTA opened at $2.53 on Thursday. The firm’s 50 day moving average is $2.63 and its 200-day moving average is $2.47. The stock has a market capitalization of $22.16 million, a P/E ratio of -1.13 and a beta of 0.93. Lisata Therapeutics has a 12-month low of $1.87 and a 12-month high of $4.20.

Hedge Funds Weigh In On Lisata Therapeutics

Hedge funds have recently made changes to their positions in the business. Cerity Partners LLC acquired a new position in shares of Lisata Therapeutics in the 2nd quarter worth approximately $32,000. Citadel Advisors LLC purchased a new position in shares of Lisata Therapeutics in the fourth quarter worth approximately $69,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Lisata Therapeutics by 45.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 25,226 shares of the company’s stock worth $75,000 after acquiring an additional 7,886 shares in the last quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.